Baseline Productions

Baseline Productions Enterprise Value

The Enterprise Value (EV) of Baseline Productions (BSSP) as of Nov 18, 2026 is 526,371.89 USD. In the previous year, Enterprise Value (EV) was 525,171.89 USD — a change of 0.23% (higher).

Enterprise Value

526,371.89USD

YoY

0.23%

Last updated:

Enterprise Value (EV) of Baseline Productions is 2020 526,371.89 USD. Enterprise Value (EV) of Baseline Productions was 2019 525,171.89 USD. It decreases by 0.23% higher compared to the previous year.

The Baseline Productions Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2014
201,625.89 USD
Jan 1, 2019
525,171.89 USD
Jan 1, 2020
526,371.89 USD
The Baseline Productions Enterprise Value history
YEAREnterprise ValueYoY
526,371.89USD+0.23%
525,171.89USD+160.47%
201,625.89USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Baseline Productions Stock analysis

What does Baseline Productions do? Baseline Productions Inc develops mobile based hardware and software based products. The company focuses on commercialization of its proteins for cancer and infectious disease treatments. Its Irreversible Pepsin Fraction (IPF) technology activates the immune system to fight autoimmune diseases. IPF binds to T-cells and triggers Th1 responses that eliminate infected cells. The firm's lead compound is an IPF suspension for autoimmune disease treatment including cancer, cirrhosis, and Hepatitis C. The product IMMUNE-THERAPEUTIC PROTEIN (ITP) is a therapeutic protein derived from porcine pepsin, which is irreversible, modified, and fractionated to IPF sequence. The company sells its IPF platform technology and ITP product to healthcare providers and pharmaceutical companies. Healthcare providers use IPF for immune system activation in autoimmune disease treatment. Pharmaceutical companies purchase ITP for development into therapeutic applications. The target segments include medical institutions treating autoimmune conditions and drug manufacturers seeking novel protein-based therapies. ITP is specifically indicated for cancer, cirrhosis, and Hepatitis C treatment. Baseline Productions generates revenue through licensing IPF technology and selling ITP therapeutic protein. The IPF platform is sold as a technology solution to partners in the healthcare sector. ITP is marketed as a therapeutic product for direct sale to medical facilities. The company's primary customers are healthcare institutions and pharmaceutical firms interested in immune system-based treatments for autoimmune diseases and infectious conditions. Baseline Productions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Baseline Productions stock

Enterprise Value (EV) of Baseline Productions is 526,371.89 USD in 2020.

Enterprise Value (EV) of Baseline Productions changed from 525,171.89 USD to 526,371.89 USD, representing a 0.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Baseline Productions since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Baseline Productions with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Baseline Productions

All Key Metrics — Baseline Productions